MX2021003441A - Polipeptidos de arginasa1. - Google Patents
Polipeptidos de arginasa1.Info
- Publication number
- MX2021003441A MX2021003441A MX2021003441A MX2021003441A MX2021003441A MX 2021003441 A MX2021003441 A MX 2021003441A MX 2021003441 A MX2021003441 A MX 2021003441A MX 2021003441 A MX2021003441 A MX 2021003441A MX 2021003441 A MX2021003441 A MX 2021003441A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- relates
- polynucleotides
- arginase
- compositions
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title 1
- 108700024123 Arginases Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102100021723 Arginase-1 Human genes 0.000 abstract 1
- 101710129000 Arginase-1 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
- C12Y305/03001—Arginase (3.5.3.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1815549.9A GB201815549D0 (en) | 2018-09-24 | 2018-09-24 | Arginase1 polypeptides |
| PCT/EP2019/075731 WO2020064744A1 (en) | 2018-09-24 | 2019-09-24 | Arginase1 polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003441A true MX2021003441A (es) | 2021-06-15 |
Family
ID=64024184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003441A MX2021003441A (es) | 2018-09-24 | 2019-09-24 | Polipeptidos de arginasa1. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12194081B2 (https=) |
| EP (1) | EP3856899A1 (https=) |
| JP (1) | JP7624388B2 (https=) |
| KR (1) | KR20210091696A (https=) |
| CN (1) | CN112771159B (https=) |
| AU (1) | AU2019350356B9 (https=) |
| CA (1) | CA3113004A1 (https=) |
| GB (1) | GB201815549D0 (https=) |
| IL (1) | IL281762A (https=) |
| MX (1) | MX2021003441A (https=) |
| SG (1) | SG11202102378WA (https=) |
| WO (1) | WO2020064744A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201818576D0 (en) | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| JP2025508840A (ja) | 2022-02-24 | 2025-04-10 | アイオー バイオテック エーピーエス | アルギナーゼ２ワクチン |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5780286A (en) | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| US20110111424A1 (en) | 2001-06-21 | 2011-05-12 | Cell Signaling Technology, Inc. | Analysis of ubiquitinated polypeptides |
| US20030228583A1 (en) | 2001-10-31 | 2003-12-11 | Amacher David E. | Biomarkers of liver response |
| CA2586048C (en) | 2004-10-29 | 2014-03-11 | Gregg A. Howe | Protection against herbivores |
| PT3778885T (pt) | 2008-10-31 | 2023-05-31 | Aerase Inc | Composições de arginases humanas modificadas e métodos para o tratamento do cancro |
| CN101781369A (zh) * | 2009-01-20 | 2010-07-21 | 江苏先声药物研究有限公司 | 一种重组人精氨酸酶融合蛋白及其应用 |
| ES2897635T3 (es) | 2014-04-29 | 2022-03-02 | Bio Cancer Treat International Ltd | Métodos y composiciones para modular el sistema inmunológico con la arginasa I |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| JP7211938B2 (ja) * | 2016-10-07 | 2023-01-24 | アイオー バイオテック エーピーエス | 免疫原性アルギナーゼペプチド |
-
2018
- 2018-09-24 GB GBGB1815549.9A patent/GB201815549D0/en not_active Ceased
-
2019
- 2019-09-24 WO PCT/EP2019/075731 patent/WO2020064744A1/en not_active Ceased
- 2019-09-24 CN CN201980062504.7A patent/CN112771159B/zh active Active
- 2019-09-24 JP JP2021516368A patent/JP7624388B2/ja active Active
- 2019-09-24 US US17/278,838 patent/US12194081B2/en active Active
- 2019-09-24 SG SG11202102378WA patent/SG11202102378WA/en unknown
- 2019-09-24 AU AU2019350356A patent/AU2019350356B9/en active Active
- 2019-09-24 CA CA3113004A patent/CA3113004A1/en active Pending
- 2019-09-24 EP EP19779801.0A patent/EP3856899A1/en active Pending
- 2019-09-24 MX MX2021003441A patent/MX2021003441A/es unknown
- 2019-09-24 KR KR1020217010964A patent/KR20210091696A/ko active Pending
-
2021
- 2021-03-24 IL IL281762A patent/IL281762A/en unknown
-
2024
- 2024-11-01 US US18/935,162 patent/US20250205318A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220031818A1 (en) | 2022-02-03 |
| US20250205318A1 (en) | 2025-06-26 |
| GB201815549D0 (en) | 2018-11-07 |
| KR20210091696A (ko) | 2021-07-22 |
| CA3113004A1 (en) | 2020-04-02 |
| JP2022501046A (ja) | 2022-01-06 |
| CN112771159A (zh) | 2021-05-07 |
| AU2019350356B9 (en) | 2026-01-29 |
| AU2019350356A8 (en) | 2021-05-27 |
| EP3856899A1 (en) | 2021-08-04 |
| JP7624388B2 (ja) | 2025-01-30 |
| AU2019350356A1 (en) | 2021-04-15 |
| AU2019350356B2 (en) | 2025-11-27 |
| IL281762A (en) | 2021-05-31 |
| WO2020064744A1 (en) | 2020-04-02 |
| SG11202102378WA (en) | 2021-04-29 |
| CN112771159B (zh) | 2025-02-11 |
| US12194081B2 (en) | 2025-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992232A1 (ru) | Композиции и способы для иммуноонкологии | |
| MX2019013289A (es) | Variantes de ligasa modificadas geneticamente. | |
| EA201891202A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201891201A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| MX2021015761A (es) | Polipeptidos. | |
| EA201890050A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890049A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890047A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201991116A1 (ru) | Полинуклеотиды и полипептиды аденовируса | |
| EA201891532A1 (ru) | Композиции и способы лечения гемоглобинопатий | |
| EA201890051A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201892147A1 (ru) | Бициклические соединения | |
| EA201992177A1 (ru) | Композиции на основе нирапариба | |
| CY1125996T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| EA201890858A1 (ru) | 2,4-дигидроксиникотинамиды как агонисты apj | |
| EA201892123A1 (ru) | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj | |
| MX2022007959A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| ZA202102469B (en) | Engineered dna polymerase variants | |
| EA201990159A1 (ru) | Биарилметильные гетероциклы | |
| MX2021014856A (es) | Vacuna de tgf-beta. | |
| EA202092692A1 (ru) | Аналоги рапамицина и их применения | |
| MX2025009320A (es) | Anticuerpos anti-cd19 novedosos | |
| TR201902741T4 (tr) | Kişisel Temizlik Bileşimleri |